Genotype–phenotype correlation in a cohort of Portuguese patients comprising the entire spectrum of VWD types: impact of NGS

Summary

The diagnosis of von Willebrand disease (VWD), the most common inherited bleeding disorder, is characterised by a variable bleeding tendency and heterogeneous laboratory phenotype. The sequencing of the entire VWF coding region has not yet become a routine practice in diagnostic laboratories owing to its high costs. Nevertheless, nextgeneration sequencing (NGS) has emerged as an alternative to overcome this limitation. We aimed to determine the correlation of genotype and phenotype in 92 Portuguese individuals from 60 unrelated families with VWD; therefore, we directly sequenced VWF. We compared the classical Sanger sequencing approach and NGS to assess the value-added effect on the analysis of the mutation distribution in different types of VWD. Sixty-two different VWF mutations were identified, 27 of which had not been previously described. NGS detected 26 additional mutations, contributing to a broad overview of the mutant alleles present in each VWD type. Twenty-nine probands (48.3 %) had two or more mutations; in addition, mutations with pleiotropic effects were detected, and NGS allowed an appropriate classification for seven of them. Furthermore, the differential diagnosis between VWD 2B and platelet type VWD (n = 1), Bernard–Soulier syndrome and VWD 2B (n = 1), and mild haemophilia A and VWD 2N (n = 2) was possible. NGS provided an efficient laboratory workflow for analysing VWF. These findings in our cohort of Portuguese patients support the proposal that improving VWD diagnosis strategies will enhance clinical and laboratory approaches, allowing to establish the most appropriate treatment for each patient.

Keywords

Gene mutations - von Willebrand disease - von Willebrand factor - molecular biology methods - NGS

• References

• 1 Sadler JE, Budde U, Eikenboom JCJ. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 04: 2103-2114.
• 2 Batlle J, Pérez-Rodríguez A, López-Fernández MF. Classification of von Willebrand disease. In: Federici AB, et al. editor. Von Willebrand Dis Basic Clin Asp. 1st ed.. Oxford: Wiley-Blackwell; 2011: 74-85.
• 3 Sadler JE. von Willebrand factor assembly and secretion. J Thromb Haemost 2009; 07 (Suppl. 01) 24-27.
• 4 Schneppenheim R. The pathophysiology of von Willebrand disease: therapeutic implications. Thromb Res 2011; 128 (Suppl): S3-7.
• 5 Michiels JJ, van Vliet HHDM. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management. Acta Haematol 2009; 121: 154-166.
• 6 Castaman G, Hillarp A, Goodeve A. Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis. Haemophilia 2014; 20 (Suppl. 04) 65-70.
• 7 Budde U, Favaloro E A. Laboratory diagnosis of von Willebrand disease: the phenotype. In: Federici AB, et al. editor. Von Willebrand Dis Basic Clin Asp. 1st ed.. Oxford: Wiley-Blackwell; 2011: 100-113.
• 8 Corrales I, Ramírez L, Altisent C. et al. Rapid molecular diagnosis of von Willebrand disease by direct sequencing. Detection of 12 novel putative mutations in VWF gene. Thromb Haemost 2009; 101: 570-576.
• 9 Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24: 123-134.
• 10 Corrales I, Catarino S, Ayats J. et al. High-throughput molecular diagnosis of von Willebrand disease by next generation sequencing methods. Haematologica 2012; 97: 1003-1007.
• 11 Goodeve AC. Current avenues in Von Willebrand disease research. Haematologica 2014; 08: 47-52.
• 12 Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood 2009; 114: 1158-1165.
• 13 Pérez-Rodríguez A, García-Rivero A, Lourés E. et al. Autosomal dominant C1149R von Willebrand disease: Phenotypic findings and their implications. Haematologica 2009; 94: 679-686.
• 14 Siaka C, Rugeri L, Caron C. et al. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia 2003; 09: 303-308.
• 15 Batlle J, Pérez-Rodríguez A, Corrales I. et al. Molecular and clinical profile of von Willebrand disease in Spain (PCM – EVW – ES): Proposal for a new diagnostic paradigm. Thromb Haemost 2015; 02: 1-11.
• 16 National Center for Biotechnology Information dbSNP (build 137). Available from: http://www.ncbi.nlm.nih.gov/snp Accessed July 14, 2015
• 17 1000 Genomes. A deep catalog of human genetic variation. Available from: www.1000genomes.org Accessed July 14, 2015
• 18 Richards S, Aziz N, Bale S. et al. ACMG Standards and Guidelines Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-424.
• 19 Gonzalez-Garay ML. The road from next-generation sequencing to personalized medicine. Per Med 2014; 11: 523-544.
• 20 Jian X, Boerwinkle E, Liu X. In silico tools for splicing defect prediction: a survey from the viewpoint of end users. Genet Med 2014; 16: 497-503.
• 21 Wallis Y, Payne S, Mcanulty C. et al. Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics. Available from: http://www.acgs.uk.com/media/774853/evaluation Accessed September 21, 2015
• 22 Mort M, Sterne-Weiler T, Li B. et al. MutPred Splice: machine learning-based prediction of exonic variants that disrupt splicing. Genome Biol 2014; 15: R19.
• 23 MacArthur DG, Manolio TA, Dimmock DP. et al. Guidelines for investigating causality of sequence variants in human disease. Nature 2014; 508: 469-476.
• 24 Exome Aggregation Consortium (ExAC). Cambridge, MA: Available from: http://exac.broadinstitute.org/ Accessed September 21, 2015
• 25 Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP). Seattle, WA: Available from: http://evs.gs.washington.edu/EVS/ Accessed September 21, 2015
• 26 HGMD Human gene mutation database (HGMD® Professional) from BIOBASE Corporation. Available from: www.biobase-international.com/hgmd Accessed September 21, 2015
• 27 International Society on Thrombosis and Haemostasis-Scientific and Standardisation Committee of von Willebrand Factor (ISTH-SSC). VWF Online Database (VWFdb). Available from: http://www.vwf.group.shef.ac.uk/vwd.html Accessed September 21, 2015
• 28 European Association for Haemophilia and Allied Disorders (EAHAD). Coagulation Factor Variant Databases. Available from: https://www.grenada.lumc.nl/LOVD2/VWF/home.php?select_db=VWF Accessed September 21, 2015
• 29 Hemobase. Available from: http://vwf.hemobase.com/ Accessed September 21, 2015
• 30 Goodeve A, Reitsma P, Mcvey J. Nomenclature of genetic variants in hemostasis. J Thromb Haemost 2011; 09: 852-855.
• 31 Gadisseur A, Berneman Z, Schroyens W. et al. Laboratory Diagnosis of von Willebrand Disease Type 1/2E (2A Subtype IIE), Type 1 Vicenza and Mild Type 1 Caused by Mutations in the D3, D4, B1–B3 and C1–C2 Domains of the von Willebrand Factor Gene. Acta Haematol 2009; 121: 128-138.
• 32 Michiels JJ, Gadisseur A, van der Planken M. et al. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains. Acta Haematol 2009; 121: 111-118.
• 33 Bowman M, Tuttle A, Notley C. et al. The genetics of Canadian type 3 von Willebrand disease: Further evidence for co-dominant inheritance of mutant alleles. J Thromb Haemost 2013; 11: 512-520.
• 34 Federici AB, Mannucci PM, Castaman G. et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B : a cohort study of 67 patients. Blood 2011; 113: 526-534.
• 35 Eikenboom J, Hilbert L, Ribba AS. et al. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost 2009; 7: 1304-1312.
• 36 Bellissimo DB, Christopherson PA, Flood VH. et al. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood 2012; 119: 1-3.
• 37 Riddell AF, Gomez K, Millar CM. et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. Blood 2009; 114: 3489-3496.
• 38 Corrales I, Ramírez L, Altisent C. et al. The study of the effect of splicing mutations in von Willebrand factor using RNA isolated from patients’ platelets and leukocytes. J Thromb Haemost 2011; 09: 679-688.
• 39 Casaña P, Martínez F, Haya S. et al. Q1311X: a novel nonsense mutation of putative ancient origin in the von Willebrand factor gene. Br J Haematol 2000; 111: 552-555.
• 40 Surdhar GK. Homozygous gene conversion in von Willebrand factor gene as a cause of type 3 von Willebrand disease and predisposition to inhibitor development. Blood 2001; 98: 248-250.
• 41 Schneppenheim R, Budde U. von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein. J Thromb Haemost 2011; 09 (Suppl. 01) 209-215.
• 42 Jacquemin M. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions. Acta Haematol 2009; 121: 102-105.
• 43 Johnsen JM, Auer PL, Morrison AC. et al. Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project. Blood 2013; 122: 590-597.
• 44 Wang QY, Song J, Gibbs R. et al. Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes. J Thromb Haemost 2013; 11: 261-269.
• 45 Meyer D, Fressinaud E, Mazurier C. Clinical, laboratory, and molecular markers of type 2 von Willebrand disease. In: Federici AB, Lee CA, Berntorp EE, Lillicrap D, Montgomery RR E. editor. Von Willebrand Dis Basic Clin Asp. Oxford: Wiley-Blackwell; 2011: 137-147.
• 46 Gadisseur A, Hermans C, Berneman Z. et al. Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematol 2009; 121: 71-84.
• 47 Enayat S, Ravanbod S, Rassoulzadegan M. et al. A novel D235Y mutation in the GP1BA gene enhances platelet interaction with von Willebrand factor in an Iranian family with platelet-type von Willebrand disease. Thromb Haemost 2012; 108: 946-954.
• 48 Woods I, Sanchez-Luceros A, Kempfer A. et al. C1272F: A novel type 2A von Willebrand’s disease mutation in A1 domain; its clinical significance. Haemophilia 2012; 18: 112-116.
• 49 Budde U, Schneppenheim R, Eikenboom J. et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 06: 762-771.
• 50 Castaman G, Federici A, Tosetto A. et al. Different bleeding risk in type 2A and 2M von Willebrand disease: A 2-year prospective study in 107 patients. J Thromb Haemost 2012; 10: 632-638.
• 51 Gadisseur A, van der Planken M, Schroyens W. et al. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene. Acta Haematol 2009; 121: 145-153.
• 52 Yadegari H, Driesen J, Pavlova A. et al. Insights into pathological mechanisms of missense mutations in C-terminal domains of von Willebrand factor causing qualitative or quantitative von Willebrand disease. Haematologica 2013; 98: 1315-1323.
• 53 Hampshire DJ, Abuzenadah AM, Cartwright A. et al. Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort. Thromb Haemost 2013; 110: 264-274.
• 54 Yadegari H, Driesen J, Pavlova A. et al. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients. Thromb Haemost 2012; 108: 662-671.
• 55 Zhou Y-F, Eng ET, Zhu J. et al. Sequence and structure relationships within von Willebrand factor. Thombosis Hemost 2012; 120: 449-458.
• 56 Lenting PJ, Christophe OD. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 2015; 125: 2019-2029.